Axel Hauschild

72.5k total citations · 7 hit papers
431 papers, 20.5k citations indexed

About

Axel Hauschild is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Axel Hauschild has authored 431 papers receiving a total of 20.5k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Oncology, 231 papers in Molecular Biology and 88 papers in Immunology. Recurrent topics in Axel Hauschild's work include Cutaneous Melanoma Detection and Management (187 papers), Melanoma and MAPK Pathways (167 papers) and CAR-T cell therapy research (101 papers). Axel Hauschild is often cited by papers focused on Cutaneous Melanoma Detection and Management (187 papers), Melanoma and MAPK Pathways (167 papers) and CAR-T cell therapy research (101 papers). Axel Hauschild collaborates with scholars based in Germany, United States and France. Axel Hauschild's co-authors include Dirk Schadendorf, Claus Garbe, Katharina C. Kähler, Reinhard Dummer, Jeffrey S. Weber, Ulrich Keilholz, Jean‐Jacques Grob, Carola Berking, Ralf Gutzmer and Selma Ugurel and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Axel Hauschild

415 papers receiving 20.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

2012 1.1k citations Katharina C. Kähler, Axel Hauschild et al. Journal of Clinical Oncology profile →
Melanoma

2018 1.0k citations Dirk Schadendorf, Alexander C. J. van Akkooi et al. The Lancet profile →
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

2012 1.0k citations Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine profile →
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2012 582 citations Reinhard Dummer, Axel Hauschild et al. profile →
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. The Lancet Oncology profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Omid Hamid, Philip Friedlander et al. Journal of Clinical Oncology profile →
Melanoma

2015 441 citations Dirk Schadendorf, Claus Garbe et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Axel Hauschild Germany	68	13.3k	10.0k	4.3k	3.6k	3.1k	431	20.5k
Klaus J. Busam United States	80	16.6k 1.3×	9.3k 0.9×	4.2k 1.0×	3.2k 0.9×	3.3k 1.1×	426	24.8k
Vernon K. Sondak United States	71	16.6k 1.3×	8.3k 0.8×	5.7k 1.3×	3.4k 1.0×	1.9k 0.6×	432	22.6k
Jeffrey E. Gershenwald United States	72	19.6k 1.5×	9.8k 1.0×	5.0k 1.2×	5.7k 1.6×	3.1k 1.0×	283	25.5k
Alexander M.M. Eggermont Netherlands	72	18.5k 1.4×	9.4k 0.9×	6.7k 1.6×	3.5k 1.0×	1.8k 0.6×	389	25.8k
Víctor G. Prieto United States	65	8.8k 0.7×	4.8k 0.5×	2.1k 0.5×	3.3k 0.9×	4.0k 1.3×	556	16.0k
Claus Garbe Germany	93	21.3k 1.6×	15.0k 1.5×	7.0k 1.6×	6.3k 1.8×	6.3k 2.1×	750	34.4k
Hubert Pehamberger Austria	57	8.4k 0.6×	6.0k 0.6×	3.0k 0.7×	2.9k 0.8×	2.5k 0.8×	278	15.3k
Célèste Lebbé France	57	12.8k 1.0×	4.4k 0.4×	4.4k 1.0×	2.7k 0.8×	1.5k 0.5×	543	18.0k
Kelly M. McMasters United States	69	15.0k 1.1×	6.3k 0.6×	3.4k 0.8×	5.1k 1.4×	2.1k 0.7×	434	23.5k
Richard A. Scolyer Australia	84	21.3k 1.6×	13.3k 1.3×	6.6k 1.5×	4.1k 1.1×	2.7k 0.9×	707	30.6k

Countries citing papers authored by Axel Hauschild

Since Specialization

Citations

This map shows the geographic impact of Axel Hauschild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Hauschild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Hauschild more than expected).

Fields of papers citing papers by Axel Hauschild

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Hauschild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Hauschild. The network helps show where Axel Hauschild may publish in the future.

Co-authorship network of co-authors of Axel Hauschild

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Hauschild. A scholar is included among the top collaborators of Axel Hauschild based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Hauschild. Axel Hauschild is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmitt, Max, Roman C. Maron, Achim Hekler, et al.. (2021). Hidden Variables in Deep Learning Digital Pathology and Their Potential to Cause Batch Effects: Prediction Model Study. Journal of Medical Internet Research. 23(2). e23436–e23436. 40 indexed citations

Gambichler, Thilo, Felix Kiecker, Uwe Reinhold, et al.. (2020). Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I–III patients. European Journal of Cancer. 143. 11–18. 9 indexed citations

Hauschild, Axel, Paolo A. Ascierto, Dirk Schadendorf, et al.. (2020). Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. European Journal of Cancer. 125. 114–120. 50 indexed citations

Schadendorf, Dirk, Alexander C. J. van Akkooi, Carola Berking, et al.. (2018). Melanoma. The Lancet. 392(10151). 971–984. 1029 indexed citations breakdown →

Dréno, Brigitte, Rainer Kunstfeld, Axel Hauschild, et al.. (2017). Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. The Lancet Oncology. 18(3). 404–412. 142 indexed citations

Sekulić, Aleksandar, Michael R. Migden, Nicole Basset‐Séguin, et al.. (2017). Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 17(1). 332–332. 283 indexed citations

Komatsubara, Kimberly M., Joanne Jeter, Richard D. Carvajal, et al.. (2017). Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. American Society of Clinical Oncology Educational Book. 37. 641–650. 8 indexed citations

Santiago-Walker, Ademi, Robert Gagnon, Jolly Mazumdar, et al.. (2015). Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clinical Cancer Research. 22(3). 567–574. 158 indexed citations

Maul, Lara Valeska, Katharina C. Kähler, & Axel Hauschild. (2015). Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency. JAMA Dermatology. 152(12). 1387–1387. 8 indexed citations

10.

McCusker, Margaret, Nicole Basset‐Séguin, Reinhard Dummer, et al.. (2014). Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer. 50(4). 774–783. 139 indexed citations

11.

Berking, Carola, Axel Hauschild, Oliver Kölbl, Gerson Mast, & Ralf Gutzmer. (2014). Basal Cell Carcinoma. Deutsches Ärzteblatt international. 111(22). 389–95. 70 indexed citations

12.

Ugurel, Selma, Thomas Mentzel, Jochen Utikal, et al.. (2013). Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up. Clinical Cancer Research. 20(2). 499–510. 100 indexed citations

13.

Hauschild, Axel, Helmut Breuninger, Roland Kaufmann, et al.. (2013). Brief S2k guidelines – Basal cell carcinoma of the skin. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 11(s3). 10–15. 45 indexed citations

14.

Sekulić, Aleksandar, Michael R. Migden, Anthony E. Oro, et al.. (2012). Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma. New England Journal of Medicine. 366(23). 2171–2179. 1011 indexed citations breakdown →

15.

Zimmer, Lisa, Uwe Hillen, Elisabeth Livingstone, et al.. (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology. 30(19). 2375–2383. 167 indexed citations

16.

Harbeck, Nadia, Mathias Warm, Peter Mallmann, et al.. (2010). Vol. 33, Issue 11, November 2010 / Band 33, Heft 11, November 2010. Onkologie. 33(11). 570–571. 2 indexed citations

17.

Dummer, Reinhard, Axel Hauschild, Juergen C. Becker, et al.. (2008). An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma. Clinical Cancer Research. 14(3). 856–864. 95 indexed citations

18.

Ugurel, Selma, Dirk Schadendorf, Claudia Pföhler, et al.. (2006). In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group. Clinical Cancer Research. 12(18). 5454–5463. 63 indexed citations

19.

Siegel, Robert, Axel Hauschild, C. Kettelhack, et al.. (2006). Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. European Journal of Surgical Oncology. 33(5). 627–632. 34 indexed citations

20.

Hauschild, Axel, et al.. (2001). Sicherheitsabstände bei der Exzision des primären malignen Melanoms: Diskussionsvorschläge aufgrund von Ergebnissen aus kontrollierten klinischen Studien. Der Hautarzt. 52(11). 1003–1010. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact